RU2718908C2 - Перитонеальная терапевтическая жидкость - Google Patents

Перитонеальная терапевтическая жидкость Download PDF

Info

Publication number
RU2718908C2
RU2718908C2 RU2018106122A RU2018106122A RU2718908C2 RU 2718908 C2 RU2718908 C2 RU 2718908C2 RU 2018106122 A RU2018106122 A RU 2018106122A RU 2018106122 A RU2018106122 A RU 2018106122A RU 2718908 C2 RU2718908 C2 RU 2718908C2
Authority
RU
Russia
Prior art keywords
peritoneal
therapeutic fluid
peritoneal therapeutic
acid
compound
Prior art date
Application number
RU2018106122A
Other languages
English (en)
Russian (ru)
Other versions
RU2018106122A (ru
RU2018106122A3 (enExample
Inventor
Гвидо ГРЕНЦМАНН
Original Assignee
Оптерион Хелс Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Оптерион Хелс Аг filed Critical Оптерион Хелс Аг
Publication of RU2018106122A publication Critical patent/RU2018106122A/ru
Publication of RU2018106122A3 publication Critical patent/RU2018106122A3/ru
Application granted granted Critical
Publication of RU2718908C2 publication Critical patent/RU2718908C2/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7016—Disaccharides, e.g. lactose, lactulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/14—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis
    • A61M1/28—Peritoneal dialysis ; Other peritoneal treatment, e.g. oxygenation
    • A61M1/287—Dialysates therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00—Special media to be introduced, removed or treated
    • A61M2202/0021—Special media to be introduced, removed or treated removed from and reintroduced into the body, e.g. after treatment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00—Special media to be introduced, removed or treated
    • A61M2202/04—Liquids
    • A61M2202/0413—Blood

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biochemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Anesthesiology (AREA)
  • Diabetes (AREA)
  • Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • External Artificial Organs (AREA)
RU2018106122A 2015-07-20 2016-07-19 Перитонеальная терапевтическая жидкость RU2718908C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15177544.2 2015-07-20
EP15177544.2A EP3120842A1 (en) 2015-07-20 2015-07-20 Peritoneal therapeutic fluid
PCT/EP2016/067186 WO2017013120A1 (en) 2015-07-20 2016-07-19 Peritoneal therapeutic fluid

Publications (3)

Publication Number Publication Date
RU2018106122A RU2018106122A (ru) 2019-08-20
RU2018106122A3 RU2018106122A3 (enExample) 2019-10-10
RU2718908C2 true RU2718908C2 (ru) 2020-04-15

Family

ID=53785450

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2018106122A RU2718908C2 (ru) 2015-07-20 2016-07-19 Перитонеальная терапевтическая жидкость

Country Status (23)

Country Link
US (2) US20180221303A1 (enExample)
EP (2) EP3120842A1 (enExample)
JP (1) JP6448847B2 (enExample)
KR (2) KR102266889B1 (enExample)
CN (2) CN107921009B (enExample)
AU (1) AU2016296216B2 (enExample)
BR (1) BR112018001005B1 (enExample)
CA (1) CA2990532C (enExample)
CO (1) CO2018000236A2 (enExample)
CY (1) CY1124467T1 (enExample)
DK (1) DK3324951T3 (enExample)
ES (1) ES2880796T3 (enExample)
HR (1) HRP20211319T1 (enExample)
HU (1) HUE055208T2 (enExample)
LT (1) LT3324951T (enExample)
MX (1) MX387020B (enExample)
PL (1) PL3324951T3 (enExample)
PT (1) PT3324951T (enExample)
RS (1) RS62142B1 (enExample)
RU (1) RU2718908C2 (enExample)
SI (1) SI3324951T1 (enExample)
SM (1) SMT202100428T1 (enExample)
WO (1) WO2017013120A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3381484A1 (en) 2017-03-31 2018-10-03 Opterion Health AG Carbohydrate composition for dialysis
CN108310005A (zh) * 2018-04-18 2018-07-24 浙江天瑞药业有限公司 一种抗腹膜纤维化的腹膜透析液
WO2020081654A1 (en) * 2018-10-16 2020-04-23 President And Fellows Of Harvard College Sirt1 activating compounds
WO2025265015A1 (en) * 2024-06-20 2025-12-26 Barinta Therapeutics, Inc. Flavylium cations and electrolyte complexes thereof

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2158593C2 (ru) * 1995-08-11 2000-11-10 Ву Джордж Биосовместимый водный раствор для использования при непрерывном амбулаторном перитонеальном диализе
WO2003057226A1 (en) * 2002-01-14 2003-07-17 Britannia Pharmaceuticals Limited Use of phospholipids in peritoneal dialysis
WO2005049049A1 (en) * 2003-11-17 2005-06-02 Braintree Laboratories, Inc. Therapeutic peg solution concentrate
EP1223985B1 (en) * 1999-10-15 2005-11-30 Dow Global Technologies Inc. Dialysis solution including polyglycol osmotic agent
US20090035240A1 (en) * 2007-07-31 2009-02-05 Maes Daniel H Aqueous Based Cosmetic Compositions Containing Resveratrol Derivatives And An Aqueous Phase Structuring Agent
WO2009017866A1 (en) * 2007-07-31 2009-02-05 Elc Management Llc Cosmetic compositions containing resveratrol derivatives
EP2774915A1 (en) * 2013-03-06 2014-09-10 Andrea Mattarei New derivatives of resveratrol
US9919004B2 (en) * 2012-04-24 2018-03-20 The University Of British Columbia Polymer-based dialysate

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA02001472A (es) * 1999-08-10 2002-07-02 Ml Lab Plc Metodo para suministrar agentes terapeuticos utilizando una solucion de dextrina.
JP4882054B2 (ja) * 2000-09-13 2012-02-22 独立行政法人科学技術振興機構 腹膜透析液およびその調製法
WO2003024391A2 (en) * 2001-08-16 2003-03-27 Mucosal Therapeutics, Inc. Treatment and prevention of mucositis in cancer patients
ITRM20020562A1 (it) * 2002-11-06 2004-05-07 Sigma Tau Ind Farmaceuti Uso del resveratrolo per la preparazione di un medicamento utile per il trattamento delle infezioni da virus dell'influenza.
SE524530C2 (sv) * 2002-12-10 2004-08-24 Gambro Lundia Ab Metod för att framställa en medicinsk lösning för peritonealdialys där en lösning innehållandes ett eller flera acetylerade eller deacetylerade aminosocker värme- eller strålningssteriliseras med bestämda pH-värden och med bestämda viktsprocent för att undvika att cytotoxiska produkter bildas.
US7498341B2 (en) 2004-01-31 2009-03-03 Sanofi Aventis Deutschland Gmbh Heterocyclically substituted 7-amino-4-quinolone-3-carboxylic acid derivatives, process for their preparation and their use as medicaments
US7384558B2 (en) 2004-07-26 2008-06-10 Baxter International Inc. Compositions capable of inhibiting reactive oxygen and carbonyl species
US20060292099A1 (en) * 2005-05-25 2006-12-28 Michael Milburn Treatment of eye disorders with sirtuin modulators
WO2007049796A2 (en) 2005-10-26 2007-05-03 Kao Corporation Resveratrol and/or grape leaf extract as i. a. endurance improver, anti-aging agent, muscle strength improver
US20110281957A1 (en) * 2008-11-26 2011-11-17 Lipoprotein Technologies, Inc. Enhanced bioactive formulations of resveratrol
JP5778584B2 (ja) * 2009-01-19 2015-09-16 ライコード・リミテツド カロテノイドとポリフェノールとの相乗的組み合わせ
US8637569B2 (en) 2009-10-22 2014-01-28 Api Genesis, Llc Methods of increasing solubility of poorly soluble compounds and methods of making and using formulations of such compounds
ES2365429B1 (es) * 2010-03-05 2012-09-06 Universidad De Castilla De La Mancha Solucion para dialisis peritoneal
EP2609918A1 (en) * 2011-12-27 2013-07-03 Zytoprotec GmbH Peritoneal dialysis fluid comprising a GSK-3 inhibitor
EP2695606A1 (en) * 2012-08-09 2014-02-12 ETH Zürich Liposome composition for peritoneal dialysis
CN103330715B (zh) * 2013-07-01 2015-09-02 华仁药业股份有限公司 一种抗腹膜纤维化的腹膜透析液

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2158593C2 (ru) * 1995-08-11 2000-11-10 Ву Джордж Биосовместимый водный раствор для использования при непрерывном амбулаторном перитонеальном диализе
EP1223985B1 (en) * 1999-10-15 2005-11-30 Dow Global Technologies Inc. Dialysis solution including polyglycol osmotic agent
WO2003057226A1 (en) * 2002-01-14 2003-07-17 Britannia Pharmaceuticals Limited Use of phospholipids in peritoneal dialysis
US20050182026A1 (en) * 2002-01-14 2005-08-18 Hills Brian A. Use of phospholipids in peritoneal dialysis
WO2005049049A1 (en) * 2003-11-17 2005-06-02 Braintree Laboratories, Inc. Therapeutic peg solution concentrate
US20090035240A1 (en) * 2007-07-31 2009-02-05 Maes Daniel H Aqueous Based Cosmetic Compositions Containing Resveratrol Derivatives And An Aqueous Phase Structuring Agent
WO2009017866A1 (en) * 2007-07-31 2009-02-05 Elc Management Llc Cosmetic compositions containing resveratrol derivatives
US9919004B2 (en) * 2012-04-24 2018-03-20 The University Of British Columbia Polymer-based dialysate
EP2774915A1 (en) * 2013-03-06 2014-09-10 Andrea Mattarei New derivatives of resveratrol

Also Published As

Publication number Publication date
PT3324951T (pt) 2021-07-20
MX387020B (es) 2025-03-19
SMT202100428T1 (it) 2021-09-14
EP3324951B1 (en) 2021-05-26
RU2018106122A (ru) 2019-08-20
SI3324951T1 (sl) 2021-09-30
DK3324951T3 (da) 2021-08-23
US11160766B2 (en) 2021-11-02
ES2880796T3 (es) 2021-11-25
AU2016296216A1 (en) 2017-12-14
RS62142B1 (sr) 2021-08-31
KR20190025759A (ko) 2019-03-11
LT3324951T (lt) 2021-07-26
HK1251176A1 (zh) 2019-01-25
HUE055208T2 (hu) 2021-11-29
US20180221303A1 (en) 2018-08-09
HRP20211319T1 (hr) 2021-11-26
EP3120842A1 (en) 2017-01-25
WO2017013120A1 (en) 2017-01-26
PL3324951T3 (pl) 2021-12-13
KR102266889B1 (ko) 2021-06-18
US20200022926A1 (en) 2020-01-23
MX2018000336A (es) 2018-05-22
JP2018522894A (ja) 2018-08-16
RU2018106122A3 (enExample) 2019-10-10
AU2016296216B2 (en) 2019-05-02
CN107921009A (zh) 2018-04-17
KR20180048577A (ko) 2018-05-10
EP3324951A1 (en) 2018-05-30
CY1124467T1 (el) 2022-07-22
BR112018001005B1 (pt) 2023-11-28
BR112018001005A2 (pt) 2022-09-06
CA2990532C (en) 2020-07-14
JP6448847B2 (ja) 2019-01-09
CO2018000236A2 (es) 2018-06-12
CN107921009B (zh) 2020-12-11
CA2990532A1 (en) 2017-01-26
CN110075307A (zh) 2019-08-02

Similar Documents

Publication Publication Date Title
US11160766B2 (en) Peritoneal therapeutic fluid
AU2016212030B2 (en) Glycan therapeutics and related methods thereof
Hao et al. Percutaneous implantation of ethanol fueled catalytic hydrogel suppresses tumor growth by triggering ferroptosis
Zhong et al. Entirely synthetic bacterial nanomimics for highly-effective tumor suppression and immune elicitation
JP6505310B2 (ja) スチルベノイドを含有する水溶液
HK40011489A (en) Peritoneal therapeutic fluid
HK1251176B (en) Peritoneal therapeutic fluid
RU2749443C2 (ru) Углеводные композиции для диализа
EP3375456B1 (en) Sustained-release topically administered agent
GB2345247A (en) Pyruvic acid formulations
CN104173288A (zh) 一种克拉霉素离子对脂质体注射液及其制备方法
Subtaweesin EFFECTS OF CURCUMIN-LOADED BACTERIAL CELLULOSE FILMS ON CANCER CELLS
HK1254524B (en) Aqueous solution comprising a stilbenoid
PL236149B1 (pl) Sposób wytwarzania środka przeciwdziałającego koagulacji krwi, środek przeciwdziałający koagulacji krwi oraz jego zastosowanie